131 related articles for article (PubMed ID: 16671078)
1. Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation.
Isaias IU; Benti R; Goldwurm S; Zini M; Cilia R; Gerundini P; Di Fonzo A; Bonifati V; Pezzoli G; Antonini A
Mov Disord; 2006 Aug; 21(8):1144-7. PubMed ID: 16671078
[TBL] [Abstract][Full Text] [Related]
2. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
[TBL] [Abstract][Full Text] [Related]
4. Prospective clinical and DaT-SPECT imaging in premotor
Sierra M; Martínez-Rodríguez I; Sánchez-Juan P; González-Aramburu I; Jiménez-Alonso M; Sánchez-Rodríguez A; Berciano J; Banzo I; Infante J
Neurology; 2017 Aug; 89(5):439-444. PubMed ID: 28679601
[TBL] [Abstract][Full Text] [Related]
5. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
6. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
[TBL] [Abstract][Full Text] [Related]
7. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
Bergareche A; Rodríguez-Oroz MC; Estanga A; Gorostidi A; López de Munain A; Castillo-Triviño T; Ruiz-Martínez J; Mondragón E; Gaig C; Lomeña F; Sarasqueta C; Tolosa E; Martí-Massó JF
Mov Disord; 2016 Mar; 31(3):335-43. PubMed ID: 26686514
[TBL] [Abstract][Full Text] [Related]
8. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
9. Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease.
Botta-Orfila T; Tolosa E; Gelpi E; Sànchez-Pla A; Martí MJ; Valldeoriola F; Fernández M; Carmona F; Ezquerra M
Neurobiol Dis; 2012 Jan; 45(1):462-8. PubMed ID: 21946334
[TBL] [Abstract][Full Text] [Related]
10. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
Adams JR; van Netten H; Schulzer M; Mak E; Mckenzie J; Strongosky A; Sossi V; Ruth TJ; Lee CS; Farrer M; Gasser T; Uitti RJ; Calne DB; Wszolek ZK; Stoessl AJ
Brain; 2005 Dec; 128(Pt 12):2777-85. PubMed ID: 16081470
[TBL] [Abstract][Full Text] [Related]
11. Common variants of LRRK2 are not associated with sporadic Parkinson's disease.
Biskup S; Mueller JC; Sharma M; Lichtner P; Zimprich A; Berg D; Wüllner U; Illig T; Meitinger T; Gasser T
Ann Neurol; 2005 Dec; 58(6):905-8. PubMed ID: 16254973
[TBL] [Abstract][Full Text] [Related]
12. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
Vilas D; Ispierto L; Álvarez R; Pont-Sunyer C; Martí MJ; Valldeoriola F; Compta Y; de Fabregues O; Hernández-Vara J; Puente V; Calopa M; Jaumà S; Campdelacreu J; Aguilar M; Quílez P; Casquero P; Lomeña F; Ríos J; Tolosa E
Parkinsonism Relat Disord; 2015 Oct; 21(10):1170-6. PubMed ID: 26306001
[TBL] [Abstract][Full Text] [Related]
13. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
[TBL] [Abstract][Full Text] [Related]
14. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.
Bonifati V
Neurochem Res; 2007 Oct; 32(10):1700-8. PubMed ID: 17440812
[TBL] [Abstract][Full Text] [Related]
16. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
[TBL] [Abstract][Full Text] [Related]
17. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-TRODAT-1 imaging of multiple system atrophy.
Lu CS; Weng YH; Chen MC; Chen RS; Tzen KY; Wey SP; Ting G; Chang HC; Yen TC
J Nucl Med; 2004 Jan; 45(1):49-55. PubMed ID: 14734673
[TBL] [Abstract][Full Text] [Related]
19. Cognitive profile and 18F-fluorodeoxyglucose PET study in LRRK2-related Parkinson's disease.
De Rosa A; Peluso S; De Lucia N; Russo P; Annarumma I; Esposito M; Manganelli F; Brunetti A; De Michele G; Pappatà S
Parkinsonism Relat Disord; 2018 Feb; 47():80-83. PubMed ID: 29249679
[TBL] [Abstract][Full Text] [Related]
20. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
